ABG
CLVS

Ally Bridge Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Ally Bridge Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-533,501
Closed -$635K – 44
2022
Q3 		$635K Buy
+533,501
New +$832K 0.42% 34

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Ally Bridge Group's CLVS Position: Q4 2022 in Review

Ally Bridge Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 533,501 shares — an estimated $635K sold.

Ally Bridge Group first reported a position in CLVS in Q3 2022 and held it in 1 quarter. The position peaked at $635K in Q3 2022. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Ally Bridge Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Ally Bridge Group sold 533,501 Clovis Oncology, Inc. shares in Q4 2022, an estimated $635K.
  • Ally Bridge Group first reported a position in Clovis Oncology, Inc. in Q3 2022 and held it in 1 quarter.
  • Ally Bridge Group's Clovis Oncology, Inc. position peaked at $635K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.